Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MME | P08473 | 5/20 | 0.44 |
| ▸ | ACE | P12821 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18970304 | 0.86 | ABCC4 (0.55) | LMNAGAAABCC4TSHRPTGS1 | |
| SCHEMBL18970284 | 0.86 | ABCC4 (0.55) | LMNAGAAABCC4TSHRPTGS1 | |
| SCHEMBL22295411 | 0.84 | LMNA (0.53) | LMNAGAAABCC4TSHRPTGS1 | |
| SCHEMBL21572800 | 0.83 | LMNA (0.51) | LMNAGAAABCC4TSHRPTGS1 | |
| SCHEMBL21249535 | 0.82 | GAA (0.47) | LMNAGAAABCC4TSHRPTGS1 | |
| SCHEMBL21572799 | 0.82 | GAA (0.47) | LMNAGAAABCC4TSHRPTGS1 | |
| SCHEMBL31558355 | 0.82 | LMNA (0.50) | LMNAGAAABCC4TSHRPTGS1 | |
| SCHEMBL31558358 | 0.82 | LMNA (0.50) | LMNAGAAABCC4TSHRPTGS1 | |
| SCHEMBL21572805 | 0.81 | ALDH1A1 (0.48) | LMNAGAAABCC4TSHRPTGS1 | |
| SCHEMBL20583485 | 0.81 | ALDH1A1 (0.50) | LMNAGAAABCC4TSHRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | DPP4, ACE, DPP8 | LMNA 1222/4885GAA 63/4885ABCC4 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.